Skip to main content
Home > Week in Review > Deals

Chronological Index of : Deals

 Current Issue
  • Daiichi Sankyo, University of California deal

    Daiichi Sankyo Co. Ltd. (Tokyo:4568), Tokyo, Japan University of California, San Francisco, Calif. Business: Neurology, Diagnostic Daiichi partnered with UCSF to discover and develop novel drugs and diagnostics for …

    Published on 4/14/2014
  • Fairjourney Biologics, Hadassah University Hospitals, Rappaport Family Institute for Research in the Medical Sciences deal

    Fairjourney Biologics, Porto, Portugal Hadassah University Hospitals, Jerusalem, Israel Rappaport Family Institute for Research in the Medical Sciences, Haifa, Israel Business: Cancer Fairjourney Biologics partnered …

    Published on 4/14/2014
  • Ferring, Merck, World Health Organization (WHO) deal

    Ferring Pharmaceuticals A/S, Saint-Prex, Switzerland Merck & Co. Inc. (NYSE:MRK), Whitehouse Station, N.J. World Health Organization (WHO), Geneva, Switzerland Business: Hematology The partners entered a deal to advance…

    Published on 4/14/2014
  • Genentech, Roche, PatientsLikeMe Inc. deal

    Genentech Inc., South San Francisco, Calif. Roche (SIX:ROG; OTCQX:RHHBY), Basel, Switzerland PatientsLikeMe Inc., Cambridge, Mass. Business: Cancer Roche's Genentech unit partnered with PatientsLikeMe to develop a …

    Published on 4/14/2014
  • Genmab, Roche deal

    Genmab A/S (CSE:GEN; OTCBB:GMXAY), Copenhagen, Denmark Roche (SIX:ROG; OTCQX:RHHBY), Basel, Switzerland Business: Pharmacogenetics Roche's Ventana Medical Systems Inc. unit partnered with Genmab to develop an …

    Published on 4/14/2014
  • GlaxoSmithKline, University of Texas MD Anderson Cancer Center deal

    GlaxoSmithKline plc (LSE:GSK; NYSE:GSK), London, U.K. University of Texas MD Anderson Cancer Center, Houston, Texas Business: Cancer The center partnered with GlaxoSmithKline to develop immunotherapies for cancer …

    Published on 4/14/2014
  • IntegraGen, Pfizer deal

    IntegraGen S.A. (Euronext:ALINT), Evry, France Pfizer Inc. (NYSE:PFE), New York, N.Y. Business: Diagnostic IntegraGen said it granted Pfizer access to evaluate IntegraGen's 56-gene molecular signature to predict …

    Published on 4/14/2014
  • IQuum, Roche deal

    IQuum Inc., Marlborough, Mass. Roche (SIX:ROG; OTCQX:RHHBY), Basel, Switzerland Business: Diagnostic, Supply/Service Roche will acquire molecular diagnostics company IQuum for $275 million in cash up front and up to $…

    Published on 4/14/2014
  • Mallinckrodt, Questcor deal

    Mallinckrodt plc (NYSE:MNK), ST. Louis, Mo. Questcor Pharmaceuticals Inc. (NASDAQ:QCOR), Anaheim, Calif. Business: Autoimmune, Inflammation Specialty pharma Mallinckrodt will acquire Questcor in a cash and stock deal …

    Published on 4/14/2014
  • Marina Biotech, Rosetta Genomics deal

    Marina Biotech Inc. (Pink:MRNA), Bothell, Wash. Rosetta Genomics Ltd. (NASDAQ:ROSG), Rehovot, Israel Business: Neurology, Diagnostic The companies partnered to discover and develop microRNA-based products to diagnose …

    Published on 4/14/2014
  • Mersana, Takeda deal

    Mersana Therapeutics Inc., Cambridge, Mass. Takeda Pharmaceutical Co. Ltd. (Tokyo:4502), Osaka, Japan Business: Cancer Mersana will use its Fleximer polymer technology to create antibody-drug conjugates (ADCs) comprised…

    Published on 4/14/2014
  • Mesoblast, Osiris deal

    Mesoblast Ltd. (ASX:MSB; Pink:MBLTY), Melbourne, Australia Osiris Therapeutics Inc. (NASDAQ:OSIR), Columbia, Md. Business: Transplant, Gene/Cell therapy Osiris said it received $15 million in cash from Mesoblast under a…

    Published on 4/14/2014
  • Oricula Therapeutics, University of Washington deal

    Oricula Therapeutics LLC, Seattle, Wash. University of Washington, Seattle, Wash. Business: Other Oricula announced it received exclusive, worldwide rights to IP from the university covering compounds to preserve …

    Published on 4/14/2014
  • Oryzon, Roche deal

    Oryzon Genomics S.A., Barcelona, Spain Roche (SIX:ROG; OTCQX:RHHBY), Basel, Switzerland Business: Hematology, Cancer Oryzon Genomics granted Roche exclusive, worldwide rights to develop and commercialize a program of …

    Published on 4/14/2014
  • Ranbaxy, Sun Pharmaceutical deal

    Ranbaxy Laboratories Ltd. (NSE:RANBAXY; BSE:500359), Gurgaon, India Sun Pharmaceutical Industries Ltd. (BSE:524715; NSE:SUNPHARMA), Mumbai, India Business: Generics Sun will acquire fellow Indian generics company …

    Published on 4/14/2014
  • Seattle Genetics, Takeda deal

    Seattle Genetics Inc. (NASDAQ:SGEN), Bothell, Wash. Takeda Pharmaceutical Co. Ltd. (Tokyo:4502), Osaka, Japan Business: Cancer Seattle Genetics will receive $6 million in milestone payments from Takeda under a 2009 deal…

    Published on 4/14/2014
  • Seek Ltd., ValiRx deal

    Seek Ltd., London, U.K. ValiRx plc (LSE:VAL), London, U.K. Business: Cancer ValiRx and Seek's Tangent Reprofiling Ltd. subsidiary established a risk-sharing JV, ValiSeek Ltd., to develop Tangent's cancer candidate …

    Published on 4/14/2014
  • Shape Pharmaceuticals, TetraLogic deal

    Shape Pharmaceuticals Inc., Cambridge, Mass. TetraLogic Pharmaceuticals Corp. (NASDAQ:TLOG), Malvern, Pa. Business: Cancer Oncology and infectious diseases company TetraLogic will acquire Shape for $13 million up front …

    Published on 4/14/2014
  • Spero Therapeutics, Roche deal

    Spero Therapeutics LLC, Cambridge, Mass. Roche (SIX:ROG; OTCQX:RHHBY), Basel, Switzerland Business: Infectious Infectious disease play Spero granted Roche the exclusive option to acquire Spero's lead antibiotic program,…

    Published on 4/14/2014
  • Starpharma, AstraZeneca deal

    Starpharma Holdings Ltd. (ASX:SPL; OTCQX:SPHRY), Melbourne, Australia AstraZeneca plc (LSE:AZN; NYSE:AZN), London, U.K. Business: Cancer, Drug delivery AstraZeneca received rights to use Starpharma's DEP dendrimer drug …

    Published on 4/14/2014
  • Strox Biopharmaceuticals, Xbiotech deal

    Strox Biopharmaceuticals LLC, Wellington, Fla. XBiotech Inc., Austin, Texas Business: Infectious XBiotech acquired Strox's patent estate for an undisclosed antibody therapy for methicillin-resistant Staphylococcus …

    Published on 4/14/2014
  • Tetra Discovery, Broad Institute of MIT and Harvard deal

    Tetra Discovery Partners LLC, Grand Rapids, Mich. Broad Institute of MIT and Harvard, Cambridge, Mass. Business: Neurology Tetra partnered with the institute's Stanley Center for Psychiatric Diseases to evaluate the …

    Published on 4/14/2014
  • AbCheck, Pierre Fabre deal

    AbCheck s.r.o., Plzen, Czech Republic Laboratoires Pierre Fabre S.A., Castres, France Business: Antibodies AbCheck will use its AbSieve discovery platform to discover antibodies against undisclosed targets from Pierre …

    Published on 4/7/2014
  • Acceleron, Celgene deal

    Acceleron Pharma Inc. (NASDAQ:XLRN), Cambridge, Mass. Celgene Corp. (NASDAQ:CELG), Summit, N.J. Business: Hematology Orphan disease company Acceleron disclosed in an SEC filing that partner Celgene is increasing its …

    Published on 4/7/2014
  • Actavis, Aurobindo deal

    Actavis plc (NYSE:ACT), Dublin, Ireland Aurobindo Pharma Ltd. (NSE:AUROPHARMA; BSE:524804), Hyderabad, India Business: Generics Aurobindo completed its acquisition of Actavis' generics commercial operations in seven …

    Published on 4/7/2014

< Previous   1  2  3  4  5  6  Next >
Subscribe Now
Free Trial

About BioCentury

Decision-shaping business intelligence for the global biotech and pharma industry since 1993